CryoLife Receives FDA Authorization to Commence PROACT Xa Clinical Trial

CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received authorization from the U.S. Food and Drug Administration (FDA) pursuant to an Investigational New Drug (IND) application to begin the PROACT Xa clinical trial, a prospective, randomized, trial to determine if patients with an On-X mechanical aortic…

Read More

Bausch Health Licenses Clearside Biomedical’s Xipereᵀᴹ (triamcinolone Acetonide Suprachoroidal Injectable Suspension), an Investigational Treatment for Macular Edema Associated With Uveitis

NDA Resubmission to the FDA Expected to Occur in the First Quarter of 2020 LAVAL, Quebec and ALPHARETTA, Ga., Oct. 23, 2019 (GLOBE NEWSWIRE) — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch + Lomb, its leading global eye health business, and Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside”), a biopharmaceutical company dedicated to…

Read More

The Art and Science of PR in the Digital Age

By Michael Toner, VP Digital Strategy   |  21, October 2019 Public relations isn’t easy. There’s a balance to our craft—a strategic mix of interpersonal grace and tactical excellence mostly foreign to other professions. Persistence, assertion, charm, and humility tie to every relationship and placement we earn. For decades, understanding the audience’s goals and interests drove our successes;…

Read More

Gene Editing Could Protect Pigs From Diseases

In the nine months between August 2018 and May 2019, 150-200 million pigs in China have become infected with African swine fever (ASF), a deadly disease that can cause pigs to die in just a few short days. Pork production is expected to fall by 25% to 35% in the country because of the virus.  The virus—which…

Read More